Treatment of Lyme borreliosis secondary and tertiary stages;Le traitement des phases secondaires et tertiaires de la borréliose de Lyme

Medecine et Maladies Infectieuses

Volumn 37, Issue 7-8, 2007, Pages 479-486

  Hansmann, Y ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Arthritis; Borrelia; Lyme disease; Meningoradiculitis

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; DALFOPRISTIN PLUS QUINUPRISTIN; DIRITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; EVERNINOMICIN; MEROPENEM; PENICILLIN G; PLACEBO; ROXITHROMYCIN; TELITHROMYCIN; TRIMETHOPRIM; UREIDOPENICILLIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ARTICLE; BORRELIA INFECTION; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG DOSE REGIMEN; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; LYME DISEASE; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY; RISK FACTOR; TREATMENT FAILURE; ANIMAL; BORRELIA BURGDORFERI; CLASSIFICATION; DERMATITIS; DISEASE MODEL; DRUG EFFECT; MICROBIOLOGY; REVIEW;

ANIMALS; ANTI-BACTERIAL AGENTS; BORRELIA BURGDORFERI GROUP; DERMATITIS; DISEASE MODELS, ANIMAL; HUMANS; LYME DISEASE; LYME NEUROBORRELIOSIS; TREATMENT FAILURE;

EID: 34548396795     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2006.01.020     Document Type: Article

References (60)

1. Steere A.C., Gross D., Meyer A.L., and Huber B.T. Auto-immune mechanism in antibiotic treatment-resistant Lyme arthitis. J. Autoimmun. 16 (2001) 263-268
2. Singh S.K., and Girschick H.J. Lyme borreliosis: from infection to autoimmunity. Clin. Microbiol. Infect. 10 (2004) 598-614
3. Lengl-Janssen B., Strauss A.F., Steere A.C., and Kamradt T. The T helper response in Lyme arthritis: differential recognition of Borrelia burgdorferi outer surface protein A in patients with treatment-resistant or treatment responsive Lyme arthritis. J. Exp. Med. 180 (1994) 2069-2078
4. 161-175 T cell epitope associated with treatment resistant Lyme arthritis: differences among the three pathogenic species of Borrelia burgdorferi sensu lato. J. Autoimmun. 23 (2004) 281-292
5. Ettestad P.J., Campbell G.L., Welbel S.F., Genese C.A., Spitalny K.C., Marchetti C.M., et al. Biliary complications in the treatment of unsubstantiated Lyme disease. J. Infect. Dis. 171 (1995) 356-361
6. Reid M.C., Schoen R.T., Evans J., Rosenberg J.C., and Horwitz R.I. The consequences of overdiagnosis and overtreatment of Lyme disease: an observational study. Ann. Intern. Med. 128 (1998) 354-362
7. Donta S.T. Tetracycline therapy for chronic Lyme disease. Clin. Infect. Dis. 25 S1 (1997) S52-S56
8. Nocton J.J., Dressler F., Rutledge B.J., Rys P.N., Persong D.H., and Steere A.C. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis. N. Engl. J. Med. 330 (1994) 229-234
9. Oksi J., Marjamaki M., Nikoskelainen J., and Viljanen M.K. Borrelia burgdorferi detected by culture and PCR in clinical relapse of disseminated Lyme borreliosis. Ann. Med. 31 (1999) 225-232
10. Hunfeld K.P., Kraiczy P., Wichelhaus T.A., Schäfer V., and Brade V. Colorimetric in vitro susceptibility of penicillins, cephalosporins, macrolides, streptogramins, tetracyclines, and aminoglycosides against Borrelia burgdorferi isolates. Int. J. Antimicrob. Agents 15 (2000) 11-17
11. Johnson R.C., Kodner C.B., Jurkovich P.J., and Collins J. Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents. Antimicrob. Agents Chemother. 34 (1999) 2133-2136
12. Hunfeld K.P., Weigand J., Wichelhaus T.A., Kekouh E., Kraiczy P., and Brade V. In vitro activity of mezlocillin, meropenem, aztreonam, vancomycin, teicoplanin, ribostamycin and fusidic acid against Borrelia burgdorferi. Intern. J. Antimicrob. Agents 17 (2001) 203-208
13. Muqing L., Toshiyuki M., Jianhui W., Masato K., and Yasutake Y. In vitro and in vivo susceptibilities of Lyme disease Borrelia isolated in China. J. Infect. Chemother. 6 (2000) 65-67
14. Hunfeld K.P., Wichelhaus T.A., Rödel R., Acker G., Brade V., and Kraiczy P. Comparison of in vitro activities of ketolides, macrolides, and an azalide against the spirochete Borrelia burgdorferi. Antimicrob. Agents Chemother. 48 (2004) 344-347
15. Alder J., Mitten M., Jarvis K., Gupta P., and Clement J. Efficacy of clarithromycin for treatment of experimental Lyme disease in vivo. Antimicrob. Agents Chemother. 37 (1993) 1329-1333
16. Levin J.M., Nelson J.A., Segreti J., Harrison B., Benson C.A., and Strle F. In vitro susceptibility of Borrelia burgdorferi to 11 antimicrobial agents. Antimicrob. Agents Chemother. 37 (1993) 1444-1446
17. Murgia R., and Cinco M. Sensitivity of Borrelia and Leptospira to quinupristin-dalfopristin in vitro. New Microbiol. 24 (2001) 193-196
18. Reisinger E.C., Wendelin I., and Gasser R. In vitro activity of trimethoprim against Borrelia burgdorferi. Eur. J. Clin. Microbiol. Infect. Dis. 16 (1997) 458-460
19. Ruzic-Sabljic E., Podreka T., Maraspin V., and Strle F. Susceptibility of Borrelia afzelii strains to antimicrobial agents. Int. J. Antimicrob. Agents 25 (2005) 474-478
20. Pavia C.S., Wormser G.P., Nowakowski J., and Cacciapuoti A. Efficacy of evernimicin (SCH27899) in vitro and in an animal model of Lyme disease. Antimicrob. Agents Chemother. 45 (2001) 936-937
21. Terekhova D., Sartakova M.L., Wormser G.P., Schwartz I., and Cabello F.C. Erythromycin resistance in Borrelia burgdorferi. Antimicrob. Agents Chemother. 46 (2002) 3637-3640
22. Hunfeld K.P., Ruzic-Sabljic E., Norris D.E., Kraiczy P., and Strle F. In vitro susceptibility testing of Borrelia burgdorferi sensu lato isolates cultured from patients with erythema migrans before and after antimicrobial chemotherapy. Antimicrob. Agents Chemother. 49 (2005) 1294-1301
23. Dotevall L., and Hagberg L. Penetration of doxycycline into cerebrospinal fluid in patients treated for suspected Lyme neuroborreliosis. Antimicrob. Agents Chemother. 33 (1989) 1078-1080
24. Kazragis R.J., Dever L.L., Jorgensen J.H., and Barbour A.G. In vivo activities of ceftriaxone and vancomycin against Borrelia spp. In the mouse brain and other sites. Antimicrob. Agents Chemother. 40 (1996) 2632-2636
25. Moody K.D., Adams R.L., and Barthold S.W. Effectiveness of antimicrobial treatment against Borrelia burgdorferi infection in mice. Antimicrob. Agents Chemother. 38 (1994) 1567-1572
26. Pavia C., Inchiosa M.A., and Wormser G.P. Efficacy of short-course therapy for Borrelia burgdorferi infection in C3H mice. Antimicrob. Agents Chemother. 46 (2002) 132-134
27. Steere A.C., Pachner A.R., and Malawista S.E. Neurologic abnormalities of Lyme disease: successful treatment with high-dose intravenous penicillin. Ann. Intern. Med. 99 (1983) 767-772
28. Steere A.C., Green J., Schoen R.T., Taylor E., Hutchinson G.J., Rahn D.W., et al. Successful parenteral penicillin therapy of established Lyme arthritis. N. Engl. J. Med. 312 (1985) 869-874
29. Eichenfield A.H., Goldsmith D.P., Benach J.L., Ross A.H., Loeb F.X., Doughty R.A., et al. Childhood arthritis: experience in an endemic area. J. Pediatr. 109 (1986) 753-758
30. Dattwyler R.J., Halperin J.J., Pass H., and Luft B.J. Ceftriaxone as effective therapy in refractory Lyme disease. J. Infect. Dis. 155 (1987) 1322-1324
31. Dattwyler R.J., Halperin J.J., Volkman D.J., and Luft B.J. Treatment of late Lyme borreliosis randomised comparison of ceftriaxone and penicillin. Lancet 1 8596 (1988) 1191-1194
32. Mulleger R.R., Millner M.M., Stanek G., and Spork K.D. Penicillin G sodium and ceftriaxone in the treatment of neuroborreliosis in children a prospective study. Infection 19 (1991) 279-283
33. Pfister H.W., Preac-Mursic V., Wilske B., and Einhaupl K.M. Cefotaxime vs penicillin G for acute neurologic manifestations in Lyme borreliosis: a prospective randomized study. Arch. Neurol. 46 (1989) 1190-1194
34. Pfister H.W., Preac-Mursic V., Wilske B., Schielke E., Sorgel F., and Einhaupl K.M. Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis. J. Infect. Dis. 19 (1991) 279-283
35. Borg R., Dotevall L., Hagberg L., Maraspin V., Lotric-Furlan S., Cimperman J., et al. Intravenous ceftriaxone compared with oral doxycycline for the treatment of Lyme neuroborreliosis. Scand. J. Infect. Dis. 37 (2005) 449-454
36. Dattwyler R.J., Luft B.J., Kunkel M.J., Finkel M.F., Wormser G.P., Rush T.J., Grunwaldt E., et al. Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme borreliosis. N. Engl. J. Med. 337 (1997) 289-294
37. Karlsson M., Hammers-Berggren S., Lindquist L., Stiernstedt G., and Svenugsson B. Comparison of intravenous penicillin G and oral doxycycline for treatment of Lyme neuroborreliosis. Neurology 44 (1994) 1203-1207
38. Logigian E.L., Kaplan R.F., and Steere A.C. Successful treatment of Lyme encephalopathy with intravenous ceftriaxone. J. Infect. Dis. 180 (1999) 377-383
39. Logigian E.L., Kaplan R.F., and Steere A.C. Chronic neurologic manifestations of Lyme disease. N. Engl. J. Med. 323 (1990) 1438-1444
40. Dotevall L., and Hagberg L. Successful oral doxycycline treatment of Lyme disease-associated facial palsy and meningitis. Clin. Infect. Dis. 28 (1999) 569-574
41. Rohacova H., Hancil J., Hulinska D., Mailer H., and Havlik J. Ceftriaxone in the treatment of Lyme neuroborreliosis. Infection 24 (1996) 88-90
42. Kaiser R. Verlauf der akuten une chronischen Neuroborreliose nach behandlung mit ceftriaxon. Nervenarzt 75 (2004) 553-557
43. Thorstrand C., Belfrage E., Bennet R., Malmborg P., and Eriksson M. Successful treatment of neuroborreliosis with ten day regimens. Pediatr. Infect. Dis. 21 (2002) 1142-1145
44. Caperton E.M., Heim-Dutoit K.M., Matzke G.M., Peterson P.K., and Johnson R.C. Ceftriaxone therapy of chronic inflammatory arthritis. A double-blind placebo controlled trial. Arch. Intern. Med. 150 (1990) 1677-1682
45. Steere A.C., Levin R.E., Molloy P.J., Kalish R.A., Abraham J.H., Liu N.Y., et al. Treatment of Lyme arthritis. Arthritis Rheum. 37 (1994) 878-888
46. Cimmino M.A., and Accardo S. Long-term treatment of chronic Lyme arthritis with benzathine penicillin. Ann. Rheum. Dis. 51 (1992) 1007-1008
47. Eckman M.H., Steere A.C., Kalish R.A., and Pauker S.G. Cost-effectiveness of oral as compared with intravenous antibiotic therapy for patients with early Lyme disease of Lyme arthritis. N. Engl. J. Med. 337 (1997) 357-363
48. Oksi J., Nikoskelainen J., and Viljanen M.K. Comparison of oral cefixime and intravenous ceftriaxone followed by oral amoxicillin in disseminated Lyme borreliosis. Eur. J. Clin. Microbiol. Infect. Dis. 17 (1998) 715-719
49. Renaud I., Cachin C., and Gerster J.C. Good outcomes of Lyme arthritis in 24 patients in an endemic area of Switzerland. Joint Bone Spine 71 (2004) 39-43
50. Valesova H., Mailer J., Havlik J., Hulinska D., and Hercogova J. Long-term results in patients with Lyme arthritis following treatment with ceftriaxone. Infection 24 (1996) 98-102
51. Dattwyler R.J., Wormser G.P., Rush T.J., Finkel M.F., Schoen R.T., Grunwaldt E., et al. A comparison of two treatment regimens of ceftriaxone in late Lyme disease. Wien. Klin. Wochenschr. 117 (2005) 393-397
52. Kaplan R.F., Trevino R.P., Johnson G.M., Levy L., Dornbush R., Hu L.T., et al. Cognitive function inj post-treatment Lyme disease. Do additional antibiotics help?. Neurology 60 (2003) 1916-1922
53. Klempner M.S., Hu L.D., Evans J., Schmid C.H., Johnson G.M., Trevino R.P., et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N. Engl. J. Med. 345 (2001) 85-92
54. Krupp L.B., Hyman L.G., Grimson R., Coyle P.K., Melville P., Ahnn S., et al. Study and treatment of post Lyme disease (STOP-LD). A randomized double masked clinical trial. Neurology 60 (2003) 1923-1930
55. Aberer E., Breier F., Stanek G., and Schmidt B. Success and failure in the treatment of acrodermatitis chronica atrophicans. Infection 24 (1996) 85-87
56. Weber K., Preac-Mursic V., Neubert U., Thurmayr R., Herzzr P., Wilske B., et al. Antibiotic therapy of early European Lyme borreliosis and acrodermatitis chronica atrophicans. Ann. N. Y. Acad. Sci. 539 (1988) 324-345
57. Kindstrand E., Nilsson B.Y., Hovmark A., Pirskanen R., and Asbrink E. Peripheral neuropathy in acrodermatitis chronica atyrophicans: effect of treatment. Acta Neurol. Scand. 106 (2002) 253-257
58. Donta S.T. Macrolide therapy of chronic Lyme disease. Med. Sci. Monit. 9 (2003) 136-142
59. Wormser G.P., Nadelman R.B., Dattwyler R.J., Dennis D.T., Shapiro E.D., Steere A.C., et al. Practice guidelines for the treatment of Lyme disease. Clin. Infect. Dis. 31 suppl (2000) S1-S14
60. Fishman R.A. Blood-brain and CSF barriers to penicillin and related organic acids. Arch. Neurol. 15 (1966) 113-124